Education, Science, Technology, Innovation and Life
Open Access
Sign In

Mechanism of "Huang Qi-Yin Yang Huo" on the Treatment of Osteoporosis by Active Components Based on Network Pharmacology and Molecular Docking

Download as PDF

DOI: 10.23977/medsc.2023.040405 | Downloads: 6 | Views: 152


Changwen Zhou 1, Lixue Yang 1, Hongzhong Ma 2, Ce Liu 2


1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712000, China

Corresponding Author

Lixue Yang


Objective: To investigate the effect of Huang Qi-Yin Yang Huo on osteoporosis (OP) by means of network pharmacology and molecular docking, in order to provide a basis for its basic research and clinical application. Methods: The active components and targets of the drug pair were obtained by means of TCMSP database and literature supplement. OMIM, GeneCards, DisGeNet, TTD and DrugBank databases were used to screen the targets related to osteoporosis, and Wayne tool was used to obtain the intersection targets. CytoScape 3.7.2 software was used to construct the "drug-ingredient-disease" network and screen core components according to node-degree values. Protein interaction network (PPI) was constructed with STRING 11.5, and core targets were screened according to node-degree values. Metascape was used for gene ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Gene and Genes (KEGG) pathway enrichment analysis, and the interactions between core components and core targets were verified by molecular docking. Results: 46 kinds of active components were identified by drug pair screening, and 128 intersection targets were identified. The target protein enrichment pathways included MAPK signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway and estrogen signaling pathway. The results of Molecular docking showed that the core components had good binding ability with the core target. Conclusion: Huang Qi-Yin Yang Huo may treat osteoporosis through multi-target and multi-pathway treatment, mainly regulating osteoblast differentiation, osteoclast inhibition, cell apoptosis and inflammation regulation, etc., providing a new idea and method for further research on the mechanism of osteoporosis in the future. 


Network pharmacology; Osteoporosis; Huang Qi; Yin Yang Huo; Molecular docking; Mechanism of action


Changwen Zhou, Lixue Yang, Hongzhong Ma, Ce Liu, Mechanism of "Huang Qi-Yin Yang Huo" on the Treatment of Osteoporosis by Active Components Based on Network Pharmacology and Molecular Docking. MEDS Clinical Medicine (2023) Vol. 4: 29-41. DOI:


[1] Salari Nader, Ghasemi Hooman, Mohammadi Loghman, Behzadi Mohammad hasan, Rabieenia Elham, Shohaimi Shamarina, Mohammadi Masoud. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis [J]. Journal of Orthopaedic Surgery and Research,2021,16(1).
[2] Zhu Xiaoyu, Zhang Weiguang, Zhao Zhi-gang. Research status of drug therapy for osteoporosis at home and abroad [J]. The Chinese Journal of Clinical Pharmacology, 2020, 36(05): 588-92.
[3] Qiu Yue, Yu Rong, Xiong Tao, Wu Wenjie. Study on the medication regularity of traditional Chinese medicine in treatment of primary osteoporosis [J]. Chinese Journal of Osteoporosis, 2022, 28(01): 75-9.
[4] Jinlong Ru, Peng Li, Jinan Wang, Wei Zhou, Bohui Li, Chao Huang, Pidong Li, Zihu Guo, Weiyang Tao, Yinfeng Yang, Xue Xu, Yan Li, Yonghua Wang, Ling Yang. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines [J]. J. Cheminformatics,2014,6(1).
[5] Yang Liu, Zhang Wangning, Liu Yuetao, Li Aiping, Qin Xuemei. Mechanistic analysis of Astragali Radix in treatment of nephrotic syndrome using network pharmacology [J]. Chinese Traditional and Herbal Drugs, 2019, 50(08): 1828-37.
[6] Song Jianbo, Liao Hui, Li Yuanping. Mechanism exploration of Astragali Radix in treatment of diabetic nephropathy based on network pharmacology [J]. Chinese Traditional and Herbal Drugs, 2020, 51(11): 2988-96.
[7] Amberger Joanna S, et al. Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders [J]. Nucleic acids research,2015,43(Database issue).
[8] Janet P , Àlex B , Núria Q , et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants [J]. Nucleic acids research,2017,45(D1):D833-D839.
[9] Zhou Ying, et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents [J]. Nucleic acids research,2021,50(D1):D1398-D1407.
[10] Wishart David S, et al. DrugBank 5.0: a major update to the DrugBank database for 2018 [J]. Nucleic acids research,2018,46(D1):D1074-D1082.
[11] Bardou Philippe, et al. jvenn: an interactive Venn diagram viewer [J]. BMC bioinformatics,2014,15(1):293.
[12] Szklarczyk Damian, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets [J]. Nucleic acids research,2019,47(D1):D607-D613.
[13] Sunghwan K , Jie C , Tiejun C , et al. PubChem in 2021: new data content and improved web interfaces [J]. Nucleic acids research, 2021, 49(D1): D1388-D1395.
[14] BURLEY S K, BHIKADIYA C, BI C, et al. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences [J]. Nucleic acids research, 2021, 49(D1): D437-D451.
[15] Zhang Yuqi, et al. AutoDock CrankPep: combining folding and docking to predict protein-peptide complexes [J]. Bioinformatics (Oxford, England), 2019, 35(24): 5121-5127.
[16] Eberhardt Jerome, et al. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings [J]. Journal of chemical information and modeling, 2021, 61(8): 3891-3898.
[17] Zhao Jingjing, et al. Prevalence and influencing factors of osteoporosis among adults in Hebei province [J]. Chinese Journal of Public Health, 2022, 38(06): 749-751.
[18] Wong Sok Kuan, et al. Quercetin as an Agent for Protecting the Bone: A Review of the Current Evidence [J]. International journal of molecular sciences, 2020, 21(17).
[19] Wong Sok Kuan, et al. The Osteoprotective Effects Of Kaempferol: The Evidence From In Vivo And In Vitro Studies [J]. Drug design, development and therapy, 2019, 13: 3497-514.
[20] KIM T H, JUNG J W, HA B G, et al. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss [J]. The Journal of nutritional biochemistry, 2011, 22(1): 8-15.
[21] Fan Jun, Cao Liping. Isorhamnetin activates p38 signaling to promote osteogenic differentiation of murine mesenchymal stem cells [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2021, 15(04): 432-7.
[22] MUKHERJEE A, LARSON E A, KLEIN R F, et al. Distinct actions of akt1 on skeletal architecture and function [J]. PloS one, 2014, 9(3): e93040.
[23] Yu Tao, et al. p53 plays a central role in the development of osteoporosis [J]. Aging, 2020, 12(11): 10473-87.
[24] WANG T, HE C. TNF-α and IL-6: The Link between Immune and Bone System [J]. Current drug targets, 2020, 21(3): 213-27.
[25] DUAN X, MURATA Y, LIU Y, et al. Vegfa regulates perichondrial vascularity and osteoblast differentiation in bone development [J]. Development (Cambridge, England), 2015, 142(11): 1984-91.
[26] Xiao Yaping, et al. Review for treatment effect and signaling pathway regulation of kidney-tonifying traditional Chinese medicine on osteoporosis [J]. China Journal of Chinese Materia Medica, 2018, 43(01): 21-30.
[27] Li ihuo. The study on psoralen stimulating osteoblast proliferation by activating 1VF-kB-MAPK signaling [D]. Guangzhou University of Chinese Medicine, 2016.
[28] PENG X D, XU P Z, CHEN M L, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2 [J]. Genes & development, 2003, 17(11): 1352-65.
[29] NAKAMURA T, IMAI Y, MATSUMOTO T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts [J]. Cell, 2007, 130(5): 811-23.

Downloads: 2922
Visits: 108133

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.